The FDA on May 25 approved Myovant Sciences’ and Pfizer’s Myfembree for the treatment of heavy menstrual bleeding caused by uterine fibroids in premenopausal women. In a Phase 3 trial, women taking Myfembree saw reductions in menstrual blood loss of more than 80%. Myovant and Pfizer will have to compete against AbbVie and Neurocrine Biosciences’ Oriahnn, which the FDA approved in May 2020 as the first-ever oral therapy for uterine fibroids. While Oriahnn must be taken twice per day, Myfembree is a once-daily treatment. Under the pharmacy benefit, Oriahnn holds covered or better status for 70% of all insured lives. It holds preferred formulary placement for 44.6% of covered lives.
SOURCE: MMIT Analytics, as of 6/2/2021